India
· Delayed Price · Currency is INR Sotac Pharmaceuticals Statistics
Total Valuation
Sotac Pharmaceuticals has a market cap or net worth of INR 1.21 billion. The enterprise value is 1.52 billion.
| Market Cap | 1.21B |
| Enterprise Value | 1.52B |
Important Dates
The next estimated earnings date is Tuesday, February 4, 2025.
| Earnings Date | Feb 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Sotac Pharmaceuticals has 11.05 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 11.05M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +16.75% |
| Owned by Insiders (%) | 72.85% |
| Owned by Institutions (%) | n/a |
| Float | 3.00M |
Valuation Ratios
The trailing PE ratio is 27.14.
| PE Ratio | 27.14 |
| Forward PE | n/a |
| PS Ratio | 1.15 |
| PB Ratio | 2.77 |
| P/TBV Ratio | 2.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.47, with an EV/FCF ratio of -25.02.
| EV / Earnings | 34.14 |
| EV / Sales | 1.45 |
| EV / EBITDA | 17.47 |
| EV / EBIT | 27.59 |
| EV / FCF | -25.02 |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.55.
| Current Ratio | 1.12 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 3.21 |
| Debt / FCF | -4.60 |
| Interest Coverage | 3.33 |
Financial Efficiency
Return on equity (ROE) is 8.46% and return on invested capital (ROIC) is 4.69%.
| Return on Equity (ROE) | 8.46% |
| Return on Assets (ROA) | 3.21% |
| Return on Capital (ROIC) | 4.69% |
| Revenue Per Employee | 15.42M |
| Profits Per Employee | 655,868 |
| Employee Count | 68 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 4.92 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.24% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -7.24% |
| 50-Day Moving Average | 134.47 |
| 200-Day Moving Average | 130.58 |
| Relative Strength Index (RSI) | 38.99 |
| Average Volume (20 Days) | 4,560 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sotac Pharmaceuticals had revenue of INR 1.05 billion and earned 44.60 million in profits. Earnings per share was 4.04.
| Revenue | 1.05B |
| Gross Profit | 225.75M |
| Operating Income | 55.19M |
| Pretax Income | 42.95M |
| Net Income | 44.60M |
| EBITDA | 87.13M |
| EBIT | 55.19M |
| Earnings Per Share (EPS) | 4.04 |
Balance Sheet
The company has 5.21 million in cash and 279.88 million in debt, giving a net cash position of -274.66 million or -24.86 per share.
| Cash & Cash Equivalents | 5.21M |
| Total Debt | 279.88M |
| Net Cash | -274.66M |
| Net Cash Per Share | -24.86 |
| Equity (Book Value) | 509.35M |
| Book Value Per Share | 39.60 |
| Working Capital | 65.21M |
Cash Flow
In the last 12 months, operating cash flow was 85.52 million and capital expenditures -146.36 million, giving a free cash flow of -60.84 million.
| Operating Cash Flow | 85.52M |
| Capital Expenditures | -146.36M |
| Free Cash Flow | -60.84M |
| FCF Per Share | -5.51 |
Margins
Gross margin is 21.52%, with operating and profit margins of 5.26% and 4.25%.
| Gross Margin | 21.52% |
| Operating Margin | 5.26% |
| Pretax Margin | 4.09% |
| Profit Margin | 4.25% |
| EBITDA Margin | 8.31% |
| EBIT Margin | 5.26% |
| FCF Margin | n/a |
Dividends & Yields
Sotac Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 3.69% |
| FCF Yield | -5.03% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |